# A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers

> **NCT05087992** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 13 (actual)

## Conditions studied

- Gastrointestinal Cancer, Metastatic

## Interventions

- **DRUG:** BI 905711
- **DRUG:** FOLFIRI
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT05087992
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-24
- **Primary completion:** 2023-10-23
- **Final completion:** 2023-11-14
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2025-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05087992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05087992, "A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05087992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*